Short answer
Spero Therapeutics Inc (SPRO) filed its Q1 2018 10-Q quarterly report on May 10, 2018 for the quarter ended Mar 31, 2018.
Spero Therapeutics Inc Q1 2018 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Grant revenue $1.2M vs $1.0M YoY, up $0.1M, with no product sales
- Operating loss $10.8M vs $7.6M YoY, net loss $10.6M vs $6.4M
- R&D expense $8.9M vs $6.0M, SPR206 highest program spending at $2.6M
- Cash, equivalents and securities $75.4M; operating cash use $12.0M and marketable-securities purchases $22.8M
- Cash runway through late Q2 2019; Phase 3 SPR994 funding requires substantial additional capital
Risk Factors
- No material-change disclosure, carried-forward risks centered on continued losses and cash funding through late Q2 2019
- Regulatory risk: FDA could discount Japanese Phase 2 data, delaying SPR994’s pivotal Phase 3 pathway and increasing costs
- Operational risk: planned Phase 3 enrollment may slow because competitors target similar urinary tract infections
- Financial risk: future financing could dilute shareholders or restrict operations through debt covenants
- Compliance risk: government awards can be terminated, audited, or subject to intellectual-property claims by U.S. agencies
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Spero Therapeutics Inc quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.